Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × OTHER × Unilateral HER2 Positive Breast Cancer × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 4304 Neoplasms 3007 Prostatic Neoplasms 1886 Colorectal Neoplasms 1715 Lung Neoplasms 1538 Carcinoma, Non-Small-Cell Lung 1259 Pancreatic Neoplasms 974 Multiple Myeloma 942 Leukemia, Myeloid, Acute 942 Lymphoma 906 Head and Neck Neoplasms 876 Leukemia 849 Precursor Cell Lymphoblastic Leukemia-Lymphoma 824 Neoplasm Metastasis 783 Colonic Neoplasms 779 Ovarian Neoplasms 750 Melanoma 747 Carcinoma, Hepatocellular 747 Stomach Neoplasms 732 Rectal Neoplasms 694 Brain Neoplasms 690 Lymphoma, Non-Hodgkin 654 Leukemia, Lymphocytic, Chronic, B-Cell 616 Uterine Cervical Neoplasms 597 Lymphoma, Follicular 556 Glioblastoma 533 Recurrence 532 Hodgkin Disease 527 Esophageal Neoplasms 524 Myelodysplastic Syndromes 504

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡